Clinical Trial Update: Safety and Immunogenicity of RH5.1/Matrix-M in Adults and Infants Living in Tanzania [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety and immunogenicity of the RH5.1/Matrix-M malaria vaccine in adults and infants in Tanzania; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• RH5.1/Matrix-M malaria vaccine (RH5.1 antigen with Matrix-M adjuvant)

Snippet

Sponsor: University of Oxford | Conditions: Malaria,Falciparum | Phase 1 | Status: COMPLETED